HCV Treatment
EACS 2015: Sofosbuvir/ Ledipasvir for 8 Weeks Cures Most Hard-to-Treat Hepatitis C in Real Life
- Details
- Category: HCV Treatment
- Published on Wednesday, 28 October 2015 00:00
- Written by Liz Highleyman
Most hepatitis C patients in the GECCO German hepatitis C cohort who were treated with sofosbuvir/ledipasvir (Harvoni) for 8 weeks in a real-world clinical setting achieved sustained virological response, even those who are advised to stay on treatment for 12 weeks due to factors such as liver cirrhosis, prior treatment experience, and high HCV viral load, according to a presentation last week at the 15th European AIDS Conference in Barcelona.
FDA Warns Viekira Pak and Technivie for Hepatitis C Can Cause Serious Liver Injury
- Details
- Category: Drug Advisories & Warnings
- Published on Friday, 23 October 2015 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) issued a warning this week that recently approved interferon-free therapy for hepatitis C virus (HCV) infection can produce serious liver damage, mainly in people who already have advanced liver disease. The warning applies to AbbVie's paritaprevir/ritonavir/ombitasvir coformulation, which is sold alone as Technivie for the treatment of HCV genotype 4, and as part of the Viekira Pak regimen for HCV genotype 1; in Europe the latter regimen is sold as separate components, Viekirax and Exviera.
Coverage of IDWeek 2015
- Details
- Category: HIV Treatment
- Published on Tuesday, 06 October 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2015, October 7-11 in San Diego.
Conference highlights include new HIV therapies and treatment strategies, HIV and hepatitis C continuums of care, and comorbidities among people with HIV and HIV/HCV coinfection, as well as news about antibiotic stewardship and other infectious diseases including Ebola virus.
Full listing of coverage by topic
10/9/15
IDWeek 2015 Features HIV and Hepatitis C Prevention, Treatment, and Cure Research
- Details
- Category: HIV Treatment
- Published on Wednesday, 07 October 2015 00:00
- Written by HIVandHepatitis.com
Immediate antiretroviral therapy is the big HIV news of the year and interferon-free therapy has transformed the treatment of hepatitis C despite its high cost, experts said during an overview of "What's Hot" in the field, presented at the IDWeek 2015 conference taking place this week in San Diego. Participants also heard a keynote talk by Ian Crozier, a doctor who survived Ebola virus disease.
Achillion's Odalasvir with Sofosbuvir Cured Hepatitis C in 6-8 Weeks in Phase 2 Study
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 25 September 2015 00:00
- Written by Achillion
Achillion Pharmaceuticals' experimental NS5A inhibitor odalasvir (ACH-3102) plus Gilead Science's sofosbuvir (Sovaldi), taken without ribavirin, produced sustained virological response at 12 weeks post-treatment in all previously untreated genotype 1 hepatitis C patients treated for 6 or 8 weeks in a small Phase 2 study, according to a recent company announcement. Treatment was safe and well-tolerated.
More Articles...
- Gilead's Sofosbuvir + Velpatasvir Combo Shows Good Results in Phase 3 Trials
- ICAAC 2015: New Hepatitis C NS5A Inhibitor Looks Promising in Early Studies
- Technivie Regimen Shows Good Response Rate for People with HCV Genotype 4
- IAS 2015: International AIDS Society Conference Starts this Weekend in Vancouver
Web Design and Development by